NasdaqGS - Delayed Quote USD

Tarsus Pharmaceuticals, Inc. (TARS)

32.04 -0.17 (-0.53%)
At close: April 26 at 4:00 PM EDT
32.04 0.00 (0.00%)
After hours: April 26 at 5:32 PM EDT

Key Executives

Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Dr. Bobak R. Azamian M.D. Co-Founder, President, CEO & Chairman 962.08k -- --
Dr. Bryan Wahl J.D., M.D. General Counsel & Corporate Secretary 619.09k -- 1978
Dr. Elizabeth Yeu Lin M.D. Chief Medical Advisor & Director 286k -- 1978
Mr. Jeffrey S. Farrow CFO & Chief Strategy Officer -- -- 1962
Dr. Seshadri Neervannan Ph.D. Chief Operating Officer 486.67k -- 1968
Mr. David Nakasone Head of Investor Relations -- -- --
Ms. Adrienne Kemp Senior Director of Corporate Communications -- -- --
Mr. Matthew Rossen M.B.A. Vice President of Marketing -- -- 1978
Mr. Scott Youmans Vice President of Sales -- -- --
Ms. Dianne C. Whitfield M.S.W. Chief Human Resources Officer 578.9k -- 1977

Tarsus Pharmaceuticals, Inc.

15440 Laguna Canyon Road
Suite 160
Irvine, CA 92618
United States
949 409 1801 https://www.tarsusrx.com
Sector: 
Healthcare
Industry: 
Biotechnology
Full Time Employees: 
244

Description

Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. It is developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other infectious disease prevention. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.

Corporate Governance

Tarsus Pharmaceuticals, Inc.’s ISS Governance QualityScore as of April 1, 2024 is 7. The pillar scores are Audit: 4; Board: 7; Shareholder Rights: 8; Compensation: 9.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Recent Events

Upcoming Events

May 07, 2024 - May 13, 2024
Tarsus Pharmaceuticals, Inc. Earnings Call

Related Tickers

CNTA Centessa Pharmaceuticals plc
8.92
-0.11%
 
KRYS Krystal Biotech, Inc.
156.88
+0.77%
 
DYN Dyne Therapeutics, Inc.
24.73
+4.37%
 
SYRE Spyre Therapeutics, Inc.
33.56
+3.36%
 
CGEM Cullinan Therapeutics, Inc.
25.30
+31.43%
 
PHAT Phathom Pharmaceuticals, Inc.
9.18
+0.88%
 
MRUS Merus N.V.
45.04
+0.24%
 
APGE Apogee Therapeutics, Inc.
47.13
+2.77%
 
ARQT Arcutis Biotherapeutics, Inc.
8.47
-1.40%
 
ELYM Eliem Therapeutics, Inc.
3.9800
+17.40%